The oxygen concentrator in the corner of the living room now has a competition inquiry attached to it
What happened
On 24 September 2026, the Competition and Markets Authority (CMA) launched a merger inquiry into a deal in home healthcare. The deal is this: Dolby Medical Home Respiratory Care Limited, which trades as Vivisol, plans to buy the home oxygen services business of Air Liquide. Both companies deliver home oxygen. In practice that means the equipment, the servicing and the deliveries that keep people with long-term lung conditions supplied with oxygen where they live. The CMA is at the first stage, called Phase 1. It has set a deadline of 19 November 2026 for its Phase 1 decision, although that deadline can be extended in limited circumstances. It has also opened an invitation to comment, which closes on 1 October 2026. Anyone with a view on how the deal might affect competition in the UK can write in. The case email address is published on the CMA's case page, and the principal case officer is Hannah Street. At this stage the CMA has not found anything wrong. Opening an inquiry is the normal process when two companies that do similar things want to combine.
Why this matters
Home oxygen is easy to overlook unless you or someone you love needs it. Then it is the most important thing in the house. People use home oxygen for conditions such as COPD, pulmonary fibrosis, some heart conditions and certain cancers. In England the service is commissioned by the NHS and delivered by contracted suppliers. Patients themselves do not shop around, which is part of why this matters. When the customer is the NHS rather than the patient, the thing that protects service quality is usually competition between suppliers at contract time. Fewer suppliers can mean less pressure to keep prices down and standards up. That is precisely the question the CMA exists to ask. It is also worth naming what does not change. An inquiry does not interrupt anybody's oxygen supply. Deliveries, servicing and emergency arrangements carry on exactly as before while the CMA does its work. If you are on home oxygen, this is news about the market, not news about your treatment.
What the evidence actually says
Here the honest answer is: there is no evidence yet, and that is the point of the process. What we know for certain is the paperwork. The CMA received the information needed to begin pre-notification, announced the launch of the inquiry by notice to the parties on 24 September 2026, and published a commencement notice. The invitation to comment has been open since 11 August 2026 and closes on 1 October 2026. The Phase 1 decision is due by 19 November 2026. At Phase 1 the CMA asks a fairly narrow question: is there a realistic prospect that this merger substantially lessens competition? If the answer is yes, it can refer the deal to a deeper Phase 2 investigation. If no, the deal clears. Nothing has been decided. No finding has been made against either company. It would be wrong to read the opening of an inquiry as a verdict, and we are not going to imply one. What the CMA is asking for right now is information from people who know the sector: clinicians, commissioners, suppliers, patient groups and patients.
Qurexa perspective
We work in healthcare logistics, so this one is close to home, and we will say the useful bit rather than the flattering bit. Home healthcare lives or dies on reliability. Not on marketing, not on technology, but on whether the thing turns up when it is supposed to. A medicine that arrives two days late is not a medicine, and an oxygen cylinder that arrives late is worse. That is the standard any supplier in this space should be held to, including us. It is also the standard worth watching for after a merger, when routes, depots and staff teams often get reorganised. If you are on home oxygen and also manage regular prescriptions, the practical overlap is simple: keep your reorder dates written down in one place, so a change at one supplier does not knock the other out of step. We help with the prescription side in Lincolnshire; the oxygen side stays with your NHS-contracted provider.
Practical advice
If you or someone in your household uses home oxygen, here is what is worth doing. Carry on exactly as normal. Your supply, servicing and emergency numbers are not affected by a competition inquiry. Find your supplier's emergency contact number today and put it somewhere obvious. On the fridge is better than in a drawer. Check when your next service or delivery is due, and note it in a calendar or on your phone. Keep a spare cylinder arrangement in mind if your service provides one, and make sure whoever else lives with you knows where it is and how it works. Tell your oxygen supplier if you are going away, and give them plenty of notice. Holiday arrangements take time to organise. If you have views on the deal, you can send written representations to the CMA before 1 October 2026 through the contact details on its case page. Patient experience is genuinely useful evidence in these inquiries, and relatively few people send it in. If your service level changes in the months ahead, report it. Tell your respiratory team and your commissioner, not just the supplier.
What to know
The CMA launched a Phase 1 merger inquiry on 24 September 2026 into Vivisol's proposed purchase of Air Liquide's home oxygen services business in the UK. Comments from interested parties close on 1 October 2026, and the Phase 1 decision is due by 19 November 2026. Nothing has been found against either company. This is a routine check on whether combining two similar suppliers would reduce competition. Home oxygen services continue unchanged while the inquiry runs. If you use home oxygen, nothing about your supply changes because of this. If you have direct experience of home oxygen services, the CMA is actively asking for it, and the window is short. Sources: Competition and Markets Authority (GOV.UK), "Vivisol / Air Liquide (home oxygen services business) merger inquiry", case launched 24 September 2026, https://www.gov.uk/cma-cases/vivisol-slash-air-liquide-home-oxygen-services-business-merger-inquiry; NHS, "Home oxygen therapy", accessed 26 September 2026, https://www.nhs.uk/conditions/home-oxygen-treatment/; NHS, "Chronic obstructive pulmonary disease (COPD)", accessed 26 September 2026, https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/. This article is for general information and does not replace advice from a doctor, pharmacist, respiratory nurse or other qualified healthcare professional. Never change your oxygen flow rate or stop using prescribed oxygen without speaking to your clinical team.
Related articles
Six hours, not never: the ICU filter notice the MHRA issued today
The UK's medicines and devices regulator has issued a new safety notice to hospitals, and it is about timing. On 13 October 2026 the Medicines and Healthcare p…
Eight pages to a minister: what the data guardian says trust is worth
On 12 October 2026, the government published a letter about who should be trusted with NHS patient data. It was written by Dr Nicola Byrne, the National Data G…
Update: the tests came back, and it was not plague
This is a follow-up to a story we covered on 5 October, when nearly 200 people were being monitored after the death of a laboratory worker in Siberia. There has…